First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)
Publication
, Conference
Cortes, JE; Mauro, MJ; Visotcky, A; Tantravahi, SK; Thompson, JE; Yang, J; Baim, A; Gao, Y; Maldonado-Schmidt, S; Olig, C; Flynn, KE ...
Published in: Blood
November 5, 2024
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
6601 / 6601
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Cortes, J. E., Mauro, M. J., Visotcky, A., Tantravahi, S. K., Thompson, J. E., Yang, J., … Atallah, E. L. (2024). First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3). In Blood (Vol. 144, pp. 6601–6601). American Society of Hematology. https://doi.org/10.1182/blood-2024-207884
Cortes, Jorge E., Michael J. Mauro, Alexis Visotcky, Srinivas K. Tantravahi, James E. Thompson, Jay Yang, Arielle Baim, et al. “First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3).” In Blood, 144:6601–6601. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-207884.
Cortes JE, Mauro MJ, Visotcky A, Tantravahi SK, Thompson JE, Yang J, et al. First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3). In: Blood. American Society of Hematology; 2024. p. 6601–6601.
Cortes, Jorge E., et al. “First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3).” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 6601–6601. Crossref, doi:10.1182/blood-2024-207884.
Cortes JE, Mauro MJ, Visotcky A, Tantravahi SK, Thompson JE, Yang J, Baim A, Gao Y, Maldonado-Schmidt S, Olig C, Flynn KE, Radich JP, Atallah EL. First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3). Blood. American Society of Hematology; 2024. p. 6601–6601.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
6601 / 6601
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology